Alerta

鉴定疾病的测定方法

Resumen de: TW202542522A

Among the various aspects of the present disclosure is the provision of assay methods to identify diseases associated with orexin levels. The present teachings include methods to quantify an orexin concentration in a fluid sample, such as a cerebrospinal fluid sample, and identifying and treating diseases, including but not limited to narcolepsy and Alzheimer's disease, from the orexin concentration.

使用化学发光二氧杂环丁烷化合物检测磷酸化TAU蛋白（P-TAU）217

Resumen de: WO2025160022A1

The presently claimed and described technology provides methods for chemiluminescence-based assays for detecting phosphorylated tau (p-tau)217 in a biological sample employing 1,2 dioxetane compounds.

生物学年龄分级方法

Resumen de: WO2025101131A1

The invention relates generally to cellular biology. In particular, the specification teaches a method of detecting and quantifying cellular biological age of a cell.

DETECCION DEL RIESGO DE ENFERMEDADES ORALES MEDIADAS POR MICROORGANISMOS

Resumen de: WO2026162642A1

The current invention refers to a in vivo method for identifying the risk of an individual of suffering from a periodontal disease, comprising detecting the FUT2 gen genotype and/or the phenotype associated to the secretor status of the Lewis B antigen from a biological sample of said individual.

Improved brain architecture and biomarkers in alzheimer's disease with mesenchymal stem cells

Resumen de: WO2025137077A1

Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function and/or quality of life.

一种用于阿尔茨海默病的联检试剂盒及其应用

Resumen de: CN122487683A

0001 本发明公开了一种用于阿尔茨海默病的联检试剂盒及其应用，属于医学诊断技术领域。该试剂盒包括检测神经颗粒蛋白（NRGN）的第一检测试剂、检测β‑淀粉样蛋白42（Aβ42）的第二检测试剂和检测磷酸化tau蛋白217（p‑tau217）的第三检测试剂。本发明通过联合检测NRGN、Aβ42和p‑tau217三种标志物的水平，并依据NRGN<100 pg/mL、Aβ42<800 pg/mL、p‑tau217>0.5 pg/mL的判定规则进行综合评估，能够显著提高阿尔茨海默病诊断的灵敏度（95.8%）和特异性（92.2%），ROC曲线下面积AUC达0.956，优于任一单一标志物。本发明试剂盒以外周血、尿液和脑脊液为检测样本，无创、便捷、成本可控，适用于阿尔茨海默病的大规模筛查及临床辅助诊断。

基于MS2病毒样颗粒装载DNA的蛋白质检测方法、信号报告单元和试剂盒

Resumen de: CN122484254A

本发明涉及生物检测与体外诊断技术领域，尤其涉及一种基于MS2病毒样颗粒装载DNA的蛋白质检测方法、信号报告单元及试剂盒。方法通过将带有包装位点和检测标签序列的DNA包裹于MS2病毒样颗粒内部，并对颗粒表面进行功能化修饰，使其作为信号报告单元参与靶蛋白的夹心免疫识别；在完成特异结合后，经洗涤及核酸酶去背景处理，再对颗粒内部DNA进行扩增检测，从而实现对目标蛋白的定性和/或定量分析。本发明兼具免疫识别的高特异性、核酸扩增的高灵敏度以及MS2病毒样颗粒对内部核酸的保护作用，具有背景低、抗干扰能力强、检测灵敏度高和适于复杂生物样本检测等优点，适用于Aβ1‑42等低丰度蛋白标志物的检测。

外周血血清中组织蛋白酶H在阿尔兹海默诊治中的用途

Resumen de: CN122487652A

本发明涉及外周血血清中组织蛋白酶H在阿尔兹海默诊治中的用途，属于生物技术领域。本发明通过对CatH在AD相关样本中的表达/活性特征及其与疾病发生发展关系的研究与验证，确立血清中CatH作为AD新的诊疗靶点/生物标志物，并据此实现外周体液检测用于筛查、辅助诊断，同时为针对CatH 的抑制剂筛选与外周干预药物开发提供依据。

腺苷酸环化酶8作为阿尔茨海默症生物标志物的应用

Resumen de: CN122484279A

0001 本发明适用于生物医学及分子诊断技术领域，提供了一种腺苷酸环化酶8作为阿尔茨海默症生物标志物的应用，本发明首次发现并证实，腺苷酸环化酶8在阿尔茨海默症患者及模型小鼠的海马组织中表达水平显著升高，且其在外周血液中的表达变化与海马组织呈现高度一致性。因此，通过检测受试者血液等离体样本中腺苷酸环化酶8的表达水平，即可反映海马组织的病理改变，用于阿尔茨海默症的辅助诊断、病情评估或风险筛查。本发明突破了无法活体获取海马组织进行检测的临床限制，提供了一种无创、简便、特异性强、灵敏度高的外周血生物标志物，适用于大规模人群筛查与长期病情监测，具有显著的临床实用价值和产业化前景。

PD-MCI标志物及其筛选方法和应用

Resumen de: CN122487677A

0001 本发明提供了一种PD‑MCI标志物及其筛选方法和应用，该PD‑MCI标志物为PLEKHH2、CA1和WDR1。在本发明中通过识别的"神经连接病"机制为治疗开发开辟了新途径，而药物重定位候选药物建立了临床前验证和临床试验的明确下一步。

DISPOSITIF BIOCAPTEUR

Resumen de: FR3171721A1

L’invention concerne un dispositif permettant de mesurer le niveau d'une molécule cible telle qu'une protéine dans un échantillon de fluide d'un sujet, le dispositif comprenant un composant d'échantillonnage pour prélever le fluide du sujet ; un composant de quantification pour quantifier le niveau de la protéine cible dans l'échantillon de fluide ; et un composant de transport pour transporter le fluide du composant d'échantillonnage au composant de quantification. Figure de l’abrégé : Figure 1

一种靶向APOE蛋白HSPG结合区的单克隆抗体或其抗原结合片段、及其应用

Resumen de: CN122483194A

本申请涉及生物医药的技术领域，具体涉及一种靶向APOE蛋白HSPG结合区的单克隆抗体或其抗原结合片段、及其应用。该单克隆抗体或其抗原结合片段包括重链可变区和轻链可变区；重链可变区包括重链互补决定区CDRH1（SEQ ID NO:3）、CDRH2（SEQ ID NO:4）以及CDRH3（SEQ ID NO:5）；轻链可变区包括轻链互补决定区CDRL1（SEQ ID NO:6）、CDRL2（SEQ ID NO:7）以及CDRL3（SEQ ID NO:8）。本申请的单克隆抗体通过特异性阻断APOE与HSPG的病理性相互作用，为阿尔茨海默病等神经退行性疾病提供了一种全新的治疗策略。

一种多重数字式蛋白检测方法

Resumen de: CN122487661A

0001 本申请涉及生物检测技术领域，具体公开了一种多重数字式蛋白检测方法。本申请利用微米级亲水修饰磁珠作为模板，通过使用涡旋振荡生成均一尺寸液滴；该检测方法不需要复杂的微流控系统、芯片或仪器产生均一的液滴，操作简单，对设备依赖程度低，可在几秒内完成反应试剂的快速分割，以磁珠为模板的液滴尺寸均一。本申请可以实现磁珠高利用率，基于振荡式的磁珠液滴生成技术避免了传统数字ELISA方法中装载方式限制导致磁珠利用率低的问题，提高检测灵敏度。本申请通过磁珠的大小、荧光、颜色、形貌进行组合编码，结合基于磁珠的涡旋液滴生成技术实现了多重数字式蛋白检测方法。

一种基于斑马鱼评价样品激活乙醛脱氢酶功效的方法

Resumen de: CN122484253A

0001 本发明公开了一种基于斑马鱼评价样品激活乙醛脱氢酶功效的方法。其首先构造斑马鱼评价模型，通过酒精暴露幼鱼后检测待乙醛脱氢酶活性，若样品实验组酶活性显著高于模型组，则判定待测样品具有激活功效。本发明能在活体水平上快速、直观地评价候选物质对乙醛脱氢酶（ALDH）的激活能力，从而筛选出能够有效加速乙醛清除、减轻乙醛毒性的活性成分。

用于生物标志物采样和增强药物递送的磁性制剂

Resumen de: WO2025118073A1

The present disclosure describes formulations, methods, and devices for biomarker sampling and therapeutic delivery using magnetic formulations. When combined with the application of external magnetic fields, magnetic formulations move within the nasal cavity. Magnetic formulations provide benefits including the ability to: target or steer placement of the formulations via a magnetic field, enhance mixing of the formulation via a magnetic field, enhance biological material collection via antibody-coated magnetic beads, or enhance sample retrieval via a magnetic-tipped inserter. Example biological materials for collection include proteins, enzymes, neural stem cells, and other biomarkers.

健康状態の早期診断及び治療のためのエクソソーム関連バイオマーカーのための組成物、方法及び使用

Resumen de: WO2025024817A1

Embodiments of the instant disclosure relate to diagnosis and/or early diagnosis, intervention and/or treatment of Alzheimer's disease (AD). Certain embodiments relate to methods for identifying and isolating/analyzing an enriched population of neuronal, microglial and/or astrocytic exosomes from a sample of a subject and detecting biomarkers of interest on one or more exosomes in the enriched population to diagnose a neurodegenerative condition, Alzheimer's disease (AD), an AD-related dementia/condition, Down Syndrome (DS) or the like at an earlier stage than afforded by current therapies using minimally invasive technologies at reduced costs in time and expenses. Other embodiments relate to assessing interventions and evaluating treatment regimens for neurodegenerative disorders using approaches disclosed herein.

標的化されたタンパク質分解の改善された方法

Resumen de: WO2024256685A1

The present invention relates to a modified secreted AY-WB protein 5 (SAP05) protein, and in particular the use of the modified SAP05 protein as part of a fusion compound for use in ubiquitin-independent protein degradation. The invention also relates to methods for the use of the fusion compound in targeted protein degradation, modulating physiological responses and therapy.

一种pTau231适配体、pTau231探针、电化学生物传感器及构建方法

Resumen de: CN122484126A

0001 本发明公开了一种pTau231适配体、pTau231探针、电化学生物传感器及构建方法，属于生物检测技术领域，所述电化学生物传感器以pTau231适配体、pTau231探针为核心生物识别元件，结合免疫磁珠富集模块、TDT酶促信号放大模块和靶标探针诱导ZIF‑8原位生长信号放大模块构建而成，用于超灵敏检测pTau231蛋白。该电化学生物传感器结合了免疫磁珠富集、TDT酶促信号放大和ZIF‑8原位生长信号放大三大模块，实现了多重信号放大与高效信号转换，将蛋白信号转为核酸信号，再转为可测量的强电化学信号，实现了低丰度pTau231的高灵敏检测，检测线性范围宽，可达 。

SMART GLASSES WITH MULTI-MODAL GENERATIVE ARTIFICAL INTELLIGENCE ASSISTANT

Resumen de: US20260215689A1

0000 Smart glasses have an outward side and an inward side facing a user. A light source is attached to the outward side emits a light beam. One or more cameras are attached to the outward side to capture images or videos. The smart glasses include a processor, speakers, and one or more microphones that receive voice control or interactions. The smart glasses are coupled to a non-transitory computer readable medium and a smart phone or a tablet. The smart glasses interact with a multi-modal generative artificial intelligence assistant including a transformer with self-attention and position encoding layers that performs computer vision and natural language processing. The glasses may also have displays, touch sensors, memory, machine learning and gesture analysis, and the ability to recognize an object. The glasses may also be coupled to a wearable device with contact-based sensors.

HISTONE ACETYLATION BLOOD BIOMARKER FOR ALZHEIMER'S DISEASE

Resumen de: WO2026161742A1

Methods and materials for identifying mammals (e.g., humans) as having, or being likely to have or to develop, Alzheimer's disease are provided herein. In some cases, methods and materials for stratifying mammals with Alzheimer's disease are provided herein.

IDENTIFYING TEST MOLECULES THAT MEDIATE TARGETED DEGRADATION

Resumen de: WO2026159152A1

The present invention relates to a method for identifying test molecules capable of binding an oligomeric target protein and a RING-type E3 ligase in the presence of a fusion protein, and a cell expressing said fusion protein.

CELL TYPE CLASSIFICATION/IDENTIFICATION USING DEEP LEARNING OF CELL NUCLEAR STAINING IMAGE

Resumen de: WO2026160417A1

The present invention addresses the problem of providing: a device, a method, and a program for easily, quickly, and accurately classifying and/or identifying a cell type of a living or fixed cell, particularly a cell of the nervous system, head, or the like; and a neural network training method for the device, the method, or the program.　In the present invention, a neural network is trained by using two-dimensional and black-and-white training image data based on captured images of stained cell nuclei and training data including information related to cell types corresponding to the cells, thereby making it possible to inexpensively, quickly, and easily classify/identify a cell type with high accuracy on the basis of the image data of the stained cell nuclei for cells contained in a specimen such as cultured cells and tissue sections.

ARENAVIRUS ANTIBODIES AND USES THEREOF

Resumen de: WO2026161273A1

Disclosed herein are antibodies, including anti-GPl antibodies that cross-react with more than one New World arenavirus and methods of using the anti-GPl antibodies.

MEASUREMENT OF CYCLIC DINUCLEOTIDE IN BODY FLUID AS BIOMARKER FOR STING-RELATED DISEASE AND INVOLVEMENT OF DYSBIOSIS THEREIN

Resumen de: WO2026160477A1

The present disclosure provides a novel technique for diagnosing STING-related diseases. Specifically, the present disclosure provides: a method comprising Step (A) for measuring a cyclic dinucleotide (CDN) present in a subject or obtaining information on the presence or level of the CDN, Step (B) for determining whether the CDN is derived from the subject and/or derived from a microorganism (parasite) expected to be contained in the subject, and Step (C) for diagnosing a STING-related disease or condition on the basis of the result of the determination; a therapeutic method related thereto; and the like.

VISUALIZATION AGENT FOR VISUALIZING AGGREGATION STATE OF PROTEIN AND METHOD FOR USING VISUALIZATION AGENT

Nº publicación: WO2026160244A1 30/07/2026

Solicitante:

UNIV TOHOKU [JP]
\u56FD\u7ACB\u5927\u5B66\u6CD5\u4EBA\u6771\u5317\u5927\u5B66

Resumen de: WO2026160244A1

A visualization agent for visualizing the aggregation state of a protein according to an embodiment contains a chemical probe molecule that binds to the protein in an aggregated state to form a complex. The chemical probe molecule is an aminocoumarin analog having a leaving group that leaves due to the formation of the complex. A method for visualizing the aggregation state of a protein according to an embodiment comprises: a contact step for bringing a visualization agent into contact with an aggregated protein; and a detection step for detecting the fluorescence of a complex of the aggregated protein and the visualization agent.